Syros Pharmaceuticals Revenue 2015-2021 | SYRS

Syros Pharmaceuticals revenue from 2015 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Syros Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $15
2019 $2
2018 $2
2017 $1
2016 $0
2015 $0
2014 $
Syros Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $5
2021-03-31 $5
2020-12-31 $6
2020-09-30 $4
2020-06-30 $3
2020-03-31 $2
2019-12-31 $1
2019-09-30 $1
2019-06-30 $0
2019-03-31 $0
2018-12-31 $1
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31
2017-09-30
2017-06-30
2017-03-31 $1
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30 $0
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.295B $0.015B
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29